Related Experiment Videos
[Chemotherapy of bladder tumors]
1Service d'urologie, centre médico-chirurgical Foch, Suresnes.
La Revue Du Praticien
|February 15, 1994
Summary
Methotrexate-vinblastine-cysplatinum (M-VAC) chemotherapy shows limited precision in bladder cancer treatment. Adjuvant chemotherapy is best reserved for poor-prognosis cases, while intravesical chemotherapy is replaced by BCG.
Area of Science:
- Oncology
- Urology
- Pharmacology
Context:
- Bladder cancer treatment relies on M-VAC chemotherapy.
- Neo-adjuvant therapy achieves bladder sterilization in 20% of patients.
- Current effectiveness criteria for neo-adjuvant therapy lack precision.
Purpose:
- To evaluate the role and effectiveness of chemotherapy in bladder cancer management.
- To assess the impact of neo-adjuvant and adjuvant chemotherapy on surgical indications.
- To review the current status of intravesical chemotherapy.
Summary:
- Methotrexate-vinblastine-cysplatinum (M-VAC) chemotherapy is the standard for bladder cancer.
- Neo-adjuvant M-VAC therapy sterilizes bladders in 20% of patients, but precise effectiveness criteria are lacking, and surgical indications remain unchanged.
- Adjuvant chemotherapy's effectiveness is not firmly established, suggesting its use for poor-prognosis cancers.
- Intravesical chemotherapy has been superseded by Bacillus Calmette-Guérin (BCG) treatment.
Impact:
- Highlights the need for improved criteria to assess neo-adjuvant chemotherapy effectiveness in bladder cancer.
- Suggests a targeted approach for adjuvant chemotherapy in high-risk bladder cancer patients.
- Indicates a shift in intravesical treatment modalities towards BCG therapy.